Audit tender conclusion

Summary by AI BETAClose X

GSK plc has concluded a competitive tender process and decided to re-appoint Deloitte LLP as its external auditor for the financial year ending 31 December 2028, following the mandatory 10-year tender requirement for Public Interest Entities. Deloitte was initially appointed for the financial year ended 31 December 2018, and this re-appointment will be subject to shareholder approval at the 2028 Annual General Meeting. Further details regarding the tender process will be disclosed in GSK's 2026 Annual Report.

Disclaimer*

GSK PLC
17 July 2026
 

Issued: 17 July 2026, London UK

 

Audit tender conclusion

 

 


GSK plc today announces that, after the conclusion of a competitive tender process led by the Audit & Risk Committee, the Board has decided to re-appoint Deloitte LLP (Deloitte) as GSK's external auditor from the financial year ending 31 December 2028.

 

As a Public Interest Entity, GSK is required to tender the statutory audit every 10 years and rotate every 20. The Company initially appointed Deloitte as external auditor with effect from the financial year ended 31 December 2018.

 

A resolution to re-appoint Deloitte as GSK's external auditor with effect from the 2028 financial year will be put to GSK's shareholders for approval at the Company's 2028 Annual General Meeting.

 

Further details of this competitive tender process will be included in GSK's 2026 Annual Report.

 

V A Whyte

Company Secretary

 

17 July 2026

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

GSK (GSK)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today